A Phase 1 Study of a Recombinant Viruslike Particle Vaccine against Human Papillomavirus Type 11 in Healthy Adult Volunteers

Viruslike particles (VLPs) produced from the L1 protein of several papillomaviruses have induced protection from infection after live challenge in animal models. In the present study, the safety and immunogenicity of a human papillomavirus (HPV)–11 L1 VLP candidate vaccine were measured in a phase 1...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 2001-05, Vol.183 (10), p.1485-1493
Main Authors: Evans, Thomas G., Bonnez, William, Rose, Robert C., Koenig, Scott, Demeter, Lisa, Suzich, JoAnn A., O’Brien, Diane, Campbell, Meredith, White, Wendy I., Balsley, James, Reichman, Richard C.
Format: Article
Language:English
Subjects:
Adolescent
Adult
AL1 protein
Antibodies, Viral - blood
Antigens
Biological and medical sciences
Capsid Proteins
Cells, Cultured
Cytokines
Dosage
Female
Fundamental and applied biological sciences. Psychology
Human papillomavirus 11
Human viral diseases
Humans
Infections
Infectious diseases
Interferon-gamma - biosynthesis
Interleukin-5 - biosynthesis
Lymphocyte Activation
Major Articles
Male
Medical sciences
Microbiology
Oncogene Proteins, Viral - genetics
Oncogene Proteins, Viral - immunology
Papillomavirus Vaccines
Placebos
Species Specificity
T lymphocytes
T-Lymphocytes - immunology
Vaccination
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies
Vaccines, DNA - adverse effects
Vaccines, DNA - pharmacology
Viral diseases
Viral diseases of the lymphoid tissue and the blood. Aids
Viral Vaccines - adverse effects
Viral Vaccines - pharmacology
Virology
Viruses
Volunteerism
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Viruslike particles (VLPs) produced from the L1 protein of several papillomaviruses have induced protection from infection after live challenge in animal models. In the present study, the safety and immunogenicity of a human papillomavirus (HPV)–11 L1 VLP candidate vaccine were measured in a phase 1, dose-finding trial in humans. The vaccine was well tolerated and induced high levels of both binding and neutralizing antibodies. Marked increases in lymphoproliferation to HPV-11 L1 antigens were noted after the second vaccination. In addition, lymphoproliferation was induced after vaccination in peripheral blood mononuclear cells (PBMC) stimulated with heterologous L1 VLP antigens of HPV types 6 and 16. Statistically significant increases in HPV antigen–specific interferon–γ and interleukin-5 production were measured from PBMC culture supernatants. This candidate HPV VLP vaccine induced robust B and T cell responses, and T cell helper epitopes appear to be conserved across HPV types
ISSN:0022-1899
1537-6613
DOI:10.1086/320190